Find My Journal

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Saadettin Kılıçkap, Mahmut Gümüş, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Hacı Mehmet Türk, İrfan Çiçin, Dmitry Bentsion, Oleg Gladkov, Philip R. Clingan, Virote Sriuranpong, Naiyer A. Rizvi, Bo Gao, Siyu Li, Sue Lee, Kristina McGuire, Chieh-I Chen, Tamta Makharadze, Semra Paydaş, Marina Nechaeva, Frank Seebach, David M. Weinreich, George D. Yancopoulos, Giuseppe Gullo, Israel Lowy, Petra Rietschel

The Lancet, 2021

Başkent University, Hacettepe University Hospital, Istanbul Medeniyet University, Dnipropetrovsk State Medical Academy, Istanbul University-Cerrahpaşa, Bezmiâlem Vakıf Üniversitesi, Trakya University, Ulyanovsk Regional Oncology Center, Illawarra Health and Medical Research Institute, Wollongong Hospital, University of Wollongong, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Columbia University Irving Medical Center, Regeneron (United States), Cukurova University, International Institute of Management Arkhangelsk

Publisher Website

Abstract

An abstract is not available for this record. Please visit the publisher website for more details.

789

Citations

View on Google Scholar